中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共3条，第1-3条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC). 期刊论文
CANCER RESEARCH, 2021, 卷号: 81
作者:  Zhang, Jian;  Wang, Xiaojia;  Wang, Xian;  Hui, Aimin;  Wu, Zhuli;  Tian, Ling;  Xu, Changjiang;  Yang, Yuchen;  Zhang, Wenjing;  Hu, Xichun
收藏  |  浏览/下载：47/0  |  提交时间：2021/11/01
Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer 期刊论文
CANCER RESEARCH, 2021, 卷号: 81
作者:  Huang, Jian;  Shao, Xiying;  Cai, Li;  Shi, Yanxia;  Chen, Zhanhong;  Huang, Ping;  Yin, Yongmei;  Zhang, Lili;  Shen, Peng;  Cao, Wenming;  Ye, Weiwu;  Huang, Yuan;  Lou, Caijin;  Lei, Lei;  Zheng, Yabin;  Zou, Weibin;  Chen, Junqing;  Wang, Xiaojia
收藏  |  浏览/下载：47/0  |  提交时间：2021/04/26
EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance 期刊论文
CANCER RESEARCH, 2017, 卷号: 77, 期号: 2, 页码: 482-493
作者:  Zheng, Xiaohu;  Fan, Xiaolei;  Fu, Binqing;  Zheng, Meijuan;  Zhang, Aimei;  Zhong, Kai;  Yan, Jialai;  Sun, Rui;  Tian, Zhigang;  Wei, Haiming
浏览  |  Adobe PDF(2088Kb)  |  收藏  |  浏览/下载：186/146  |  提交时间：2018/07/04